Enalapril-d5 is intended for use as an internal standard for the quantification of enalapril by GC- or LC-MS. Enalapril is an inhibitor of angiotensin-converting enzyme (ACE; IC50 = 1.2 nM in porcine plasma).1 In vivo, enalapril (0.05-1 mg/kg, p.o.) inhibits pressor responses induced by angiotensin I in rats and dogs in a dose-dependent manner. Enalapril reduces heart rate, systolic and diastolic blood pressures, and heart weight/body weight ratio in salt-sensitive and -resistant Dahl rats fed a high-salt or low-salt diet.2 Formulations containing enalapril have been used for the treatment of hypertension, congestive heart failure, myocardial infarction, and diabetic nephropathies.3
1.Gross, D.M., Sweet, C.S., Ulm, E.H., et al.Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivoJ. Pharmacol. Exp. Ther.216(3)552-557(1981) 2.Sharma, J.N., Fernandez, P.G., Kim, B.K., et al.Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazideJ. Hypertens.1(3)251-256(1983) 3.Redelinghuys, P., Nchinda, A.T., and Sturrock, E.D.Development of domain-selective angiotensin I-converting enzyme inhibitorsAnn. N. Y. Acad. Sci.1056160-175(2005)